Elenestinib is an investigational new drug that is being evaluated by Blueprint Medicines (a Sanofi company) for the treatment of indolent and smoldering systemic mastocytosis (SM), a rare disease where excess abnormal mast cells build up in internal organs, causing allergy‑like symptoms and organ damage.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.